Summary A new method with a low pH step to dissociate serum complexes has been developed to measure serum levels of antigens associated with ovarian cancer. The antigens are detected by monoclonal antibodies HMFG1 and HMFG2 and have been compared to an existing ovarian cancer associated antigen detected by the antibody CA125. Elevated HMFG1 was found in 56%, and elevated HMFG2 in 65% of 924 sera from 85 patients with ovarian cancer. CA125 was elevated in 85% of these sera. When the three markers were used in conjunction, 95% of sera from patients with ovarian cancer were positive -compared with 7% in sera from healthy control subjects. Therefore, the combination of HMFG1, HMFG2 and CA125 increases the diagnostic accuracy. If all three markers are normal in a patient previously treated for ovarian cancer then no further positive information regarding disease status can be obtained by ultrasound and CT scanning.
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Early diagnosis of epithelial ovarian cancer is desirable because it is associated with a better prognosis (Young et al., 1982) . It is also useful to have a simple and cost effective way of monitoring response to therapy. Until recently CT scanning has been the most useful non-invasive method for tumour detection (Johnson et al., 1983) . Although second-look laparotomy can provide further information about disease status the procedure, in itself, does not improve survival (Cohen et al., 1983) . Recently a radioimmunoassay has been developed, incorporating monoclonal antibody CA 125, which is of value in monitoring the response to therapy in approximately 85% of patients with ovarian cancer (Bast et al., 1983; Canney et al., 1984) .
In this paper we describe a new method using a panel of monoclonal antibodies that can be used to measure tumour markers. In conjunction with CA 125 assay it provides a sensitive and specific system for the detection and management of epithelial ovarian cancer.
Patients and methods
Patients HMFG1, HMFG2 and CA125 levels were measured in 924 sera from 85 patients with histologically proven epithelial ovarian cancer. Sera from 5 patients with definite evidence of disease but with negative HMFG1, HMFG2 and CA125 levels were tested in a further assay measuring serum placental alkaline phosphatase (PLAP) (Tucker et al., 1985) .
Sera from 150 apparently healthy blood donors obtained from the Regional Blood Transfusion Centre were assayed for HMFG1 and HMFG2. Serum samples were stored at -20°C until required for analysis. Sera were frozen and thawed once only prior to assay.
The accompanying paper (Dhokia et al., 1986 ) describes the results of serum assays for HMFGI and HMFG2 antigens in sera from patients with neoplastic and non-neoplastic breast, liver and gastrointestinal diseases.
Chemotherapy schedules and patient assessment were as previously reported (Canney et al., 1984 globule. The mouse used for the development of HMFG2 also received cultured milk epithelial cells (Arklie et al., 1981) .
ELISA method It was suspected that one of the reasons for the failure of existing conventional 'sandwich' ELISA systems to detect small amounts of circulating antigen is that the antigen is complexed specifically or non-specifically with other serum components and therefore escapes detection by antibody. One way to expose the antigen is to disrupt complexes using acidic conditions, e.g. with citric acid, pH 2.0 (Feller et al., 1985) . We used phosphatase conjugated antibody since this simplifies the method (one step procedure) and minimises the proportion of false positive results (Ishikawa et al., 1983 ) (IQ [Biol Ltd., Cambridge) .
Twenty pl of serum was added to 250,1d citrate buffer (pH 2.0) and 50pl of this mixture was added to wells of previously glutaraldehyde treated microtitre plates. These were dried overnight at 37°C in a sterile microbiological safety cabinet to comply with Health and Safety requirements. The plates were then blocked with 0.02% gelatin and washed with 0.05% Tween 20 in PBS containing 0.2% casein. To each well, 100,l of a 400 ng ml-1 monoclonal antibody conjugate with phosphatase and diluted in PBS with Tween, was added and incubated at 4°C overnight.
Following further washes, 100 ,l of substrate buffer (one tablet of Sigma 104 phosphatase to S ml of Diethanoline (BDH) 5% w/v + 0.02,M Mg L/2) was added and incubated at 37°C in the dark for 30 min. Plates were read at 405 nm.
Assay for CA 125 and PLAP Levels of CA125 were determined using a commercially available kit (International CIS (UK) Ltd., London) according to manufacturer's instructions, and serum PLAP was measured according to an established assay method (Tucker et al., 1985) .
Results
HMFGI and HMFG2 assay Several parameters have been examined and our findings (data not shown in this manuscript) were that for HMFG1 and HMFG2 and using human milk fat globule membrane HMFG and partially deglycosylated HMFG (J. Taylor-Papadimitriou, personal communication) as antigen we could detect down to 2-4 ng HMFG in serum. We used this value as the operational cut-off level, established by examining normal blood donors, the cut-off point being the mean of all samples plus 2 s.d. Although results are expressed as optical density units they can also be converted to ngl-l HMFG antigen. For each assay a standard curve was performed. We found (data not shown) that the interassay and intraassay variations were always < 10% and usually between 3-5%. Therefore serial measurements of serum antigen levels could be confidently performed as shown in Figures la-c.
Patients
The proportion of patients with ovarian adenocarcinoma with elevated antigen levels, compared to control subjects is shown in Table I , the combined sensitivity -any marker positive -reaching 95%. Sensitivity was increased to 98.8% when a further assay for placental alkaline phosphatase (PLAP) was performed in 5 patients who had normal levels of CA125, HMFG1, HMFG2 and active ovarian cancer; three of these 5 patients had elevated serum PLAP. CA125 was detected irrespective of histological type, but of patients with mucinous tumours HMFG1 was elevated, marginally, in only one, whilst HMFG2 was elevated in none (Table  II) . The sensitivity of HMFG1 and HMFG2 in non-mucinous ovarian adenocarcinoma was 47/80 (59%) and 55/80 (69%) respectively. The absolute serum levels of all three antigens was positively correlated with increasing tumour burden (Table  III) . Increasing sensitivity as tumour bulk increased was more marked for CA125 than for HMFG2. This was not seen for HMFG1 where the antigen was detected as frequently in minimal residual disease (<2cm maximum diam.) as in bulk residual disease.
Correlation with clinical course of disease (Table  IV; Figure la- This study confirms the previously demonstrated utility of CA 125 as a marker in ovarian cancer (Bast et al., 1983; Canney et al., 1984 Patients with high levels of PLAP had a poor prognosis in agreement with previous studies (Doellgast & Homesley, 1984) . These differences may reflect cellular heterogeneity within a tumour either in terms of sensitivity to therapy or in terms of cell loss mechanisms.
Drying of serum samples at 37°C overnight does not have any more Health and Safety implications than when performing a conventional sandwich assay for the measurement of serum markets assuming that the drying process is carried out in a microbiological safety cabinet.
In conclusion, the use of this new assay method for tumour markers detected by antibodies HMFGI and HMFG2, in conjunction with another established assay CA125, is of value in the management of patients with epithelial ovarian cancer. Sera negative for HMFG1, HMFG2 and CA125 should be tested for the presence of placental alkaline phosphatase PLAP. If all markers are negative then it is extremely unlikely that active disease is present. Furthermore, in view of the high positive rate in patients with breast cancer (Dhokia et al., 1986) this panel of antibodies (HMFG1 and HMFG2) should be tested for its potential as a screening method for ovarian or breast cancer in high risk asymptomatic patients.
